Association of serum ferritin levels with non-alcoholic fatty liver disease in postmenopausal women

References

• Kim D, Touros A, Kim WR. Nonalcoholic Fatty Liver Disease and Metabolic Syndrome. Clin Liver Dis 2018;22:133–40
   PubMed Web of Science ®Google Scholar
• Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413–9
   PubMed Web of Science ®Google Scholar
• Rinella M, Charlton M. The globalisation of non-alcoholic fatty liver disease: prevalence and impact on world health. Hepatology 2016;64:19–22
   PubMed Web of Science ®Google Scholar
• Angulo P. GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2007;25:883–9
   PubMed Web of Science ®Google Scholar
• Fernández Muñoz MJ, Basurto Acevedo L, Córdova Pérez N, et al. Epicardial adipose tissue is associated with visceral fat, metabolic syndrome, and insulin resistance in menopausal women. Rev Esp Cardiol (Engl Ed) 2014;67:436–41
   PubMed Web of Science ®Google Scholar
• Peppa M, Koliaki C, Hadjidakis DI, et al. Regional fat distribution and cardiometabolic risk in healthy postmenopausal women. Eur J Intern Med 2013;24:824–31
   PubMed Web of Science ®Google Scholar
• Kabat GC, Wu WY, Bea JW, et al. Metabolic phenotypes of obesity: frequency, correlates and change over time in a cohort of postmenopausal women. Int J Obes 2017;41:170–7
   Web of Science ®Google Scholar
• Gutierrez-Grobe Y, Ponciano-Rodriguez G, Ramos MH, et al. Prevalence of nonalcoholic fatty liver disease in premenopausal postmenopausal and polycystic ovary syndrome women. The role of estrogens. Ann Hepatol 2010;9:402–9
   PubMed Web of Science ®Google Scholar
• Gao S, Zhao D, Qi Y, et al. The association between serum ferritin levels and the risk of new-onset type 2 diabetes mellitus: a 10-year follow-up of the Chinese Multi-Provincial Cohort Study. Diabetes Res Clin Pract 2017;130:154–62
   PubMed Web of Science ®Google Scholar
• Jehn M, Clark JM, Guallar E. Serum ferritin and risk of the metabolic syndrome in U.S. adults. Diabetes Care 2004;27:2422–8
   PubMed Web of Science ®Google Scholar
• Yoneda M, Nozaki Y, Endo H, et al. Serum ferritin is a clinical biomarker in Japanese patients with nonalcoholic steatohepatitis (NASH) independent of HFE gene mutation. Dig Dis Sci 2010;55:808–14
   PubMed Web of Science ®Google Scholar
• Hsiao TJ, Chen JC, Wang JD. Insulin resistance and ferritin as major determinants of nonalcoholic fatty liver disease in apparently healthy obese patients. Int J Obes 2004;28:167–72
   PubMed Web of Science ®Google Scholar
• Ryan JD, Armitage AE2, Cobbold JF, et al. Hepatic iron is the major determinant of serum ferritin in NAFLD patients. Liver Int 2018;38:164–73
   PubMed Web of Science ®Google Scholar
• Goh GB, Issa D, Lopez R, et al. The development of a non-invasive model to predict the presence of non-alcoholic steatohepatitis in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol 2016;31:995–1000
   PubMed Web of Science ®Google Scholar
• Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002;123:745–50
   PubMed Web of Science ®Google Scholar
• Takaki A, Kawai D, Yamamoto K. Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH). IJMS 2013;14:20704–28
   Google Scholar
• Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metab Clin Exp 2016;65:1038–48
   PubMed Web of Science ®Google Scholar
• Gaggini M, Morelli M, Buzzigoli E, et al. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients 2013;105:1544–60
   Google Scholar
• Cho MR, Park JK, Choi WJ, et al. Serum ferritin level is positively associated with insulin resistance and metabolic syndrome in postmenopausal women: a nationwide population-based study. Maturitas 2017;103:3–7
   PubMed Web of Science ®Google Scholar
• Fernández-Real JM, Manco M. Effects of iron overl oad on chronic metabolic diseases. Lancet Diabetes Endocrinol 2014;2:513–26
   PubMed Web of Science ®Google Scholar
• Robertson RP, Harmon JS. Diabetes, glucose toxicity, and oxidative stress: A case of double jeopardy for the pancreatic islet beta cell. Free Radic Biol Med 2006;1541:177–84
   Google Scholar
• Utzschneider KM, Largajolli A, Bertoldo A, et al. Serum ferritin is associated with non-alcoholic fatty liver disease and decreased β-cell function in non-diabetic men and women. J Diabetes Complications 2014;28:177–84
   PubMed Web of Science ®Google Scholar
• Fernández-Real JM, Peñarroja G, Castro A, et al. Blood letting in high-ferritin type 2 diabetes: effects on insulin sensitivity and beta-cell function. Diabetes. Diabetes 2002;51:1000–4
   PubMed Web of Science ®Google Scholar
• Cichoż-Lach H, Michalak A. Oxidative stress as a crucial factor in liver diseases. World J Gastroenterol 2014;20:8082–91
   PubMed Web of Science ®Google Scholar
• Graf E, Mahoney JR, Bryant RG, et al. Iron-catalyzed hydroxyl radical formation. Stringent requirement for free iron coordination site. J Biol Chem 1984;259:3620–4
   PubMed Web of Science ®Google Scholar
• Maliken BD, Nelson JE, Klintworth HM, Beauchamp M, Yeh MM, Kowdley KV. Hepatic reticuloendothelial system cell iron deposition is associated with increased apoptosis in nonalcoholic fatty liver disease. Hepatology 2013;57:1806–13
   PubMed Web of Science ®Google Scholar
• Valko M, Morris H, Cronin MT. Cronin Metals, toxicity and oxidative stress. Curr Med Chem 2005;12:1161–208
   PubMed Web of Science ®Google Scholar
• Cheng HL, Bryant C, Cook R, O'Connor H, Rooney K, Steinbeck K. The relationship between obesity and hypoferraemia in adults: a systematic review. Obes Rev 2012;13:150–61
   PubMed Web of Science ®Google Scholar
• Hagström H, Nasr P, Bottai M, et al. Elevated serum ferritin is associated with increased mortality in non-alcoholic fatty liver disease after 16 years of follow-up. Liver Int 2016;36:1688–95
   PubMed Web of Science ®Google Scholar
• Lee SS, Park SH, Kim HJ, et al. Non-invasive assessment of hepatic steatosis: prospective comparison of the accuracy of imaging examinations. J Hepatol 2010;52:579–85
   PubMed Web of Science ®Google Scholar
• van Werven JR, Marsman HA, Nederveen AJ, et al. Assessment of hepatic steatosis in patients undergoing liver resection: Comparison of US, CT, T1-weighted dual-echo MR imaging, and point-resolved 1H MR spectroscopy. Radiology 2010;256:159–68
   PubMed Web of Science ®Google Scholar
• de Moura Almeida A, Cotrim HP, Barbosa DB, et al. Fatty liver disease in severe obese patients: diagnostic value of abdominal ultrasound. Wjg 2008;14:1415–8
   PubMed Web of Science ®Google Scholar
• Palmentieri B, de Sio I, La Mura V, et al. The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. Dig Liver Dis 2006;38:485–9
   PubMedGoogle Scholar
• Pan HJ, Chang HT, Lee CH. Association between tamoxifen treatment and the development of different stages of nonalcoholic fatty liver disease among breast cancer patients. J Formos Med Assoc 2016;115:411–7
   PubMed Web of Science ®Google Scholar
• Nemoto Y, Toda K, Ono M, et al. Altered expression of fatty acid-metabolizing enzymes in aromatase-deficient mice. J Clin Invest 2000;105:1819–25
   PubMed Web of Science ®Google Scholar